Study S002336

A Randomised, Double-blind, Placebo Controlled, Double Dummy, Single-centre Trial in Healthy Subjects Comparing the Steady-state Exposure of Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly

ClinicalTrials.gov record

Registration

Registration: NCT02557620
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 113
Start: 2015-09
Primary completion: 2016-04
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Healthy
Interventions: DRUG:semaglutide; DRUG:placebo
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2014-005171-84; OTHER:U1111-1164-2741; NIH:2014

Registered primary outcomes

Area under the semaglutide concentration-time curves [At steady-state from 0 to168 hours after dosing on day 78]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.